2. シグナル伝達
  3. GPCR/G Protein
    Immunology/Inflammation
  4. CCR
  5. CCR8 Isoform

CCR8

CCR8 (C-C chemokine receptor 8) is a class A G protein-coupled chemokine receptor that primarily mediates immune-cell trafficking through interactions with the endogenous ligand CCL1, thereby regulating leukocyte migration, inflammatory positioning, and immune-cell survival programs[1][2]. Mechanistically, structural studies demonstrate that CCL1 activates CCR8 through a two-step binding process involving receptor extracellular domains and subsequent signaling activation, providing a molecular framework for CCR8-dependent chemotaxis and immune regulation[1]. In disease-associated tissues, CCR8 is highly enriched on suppressive intratumoral regulatory T cells and is linked to immunosuppressive tumor microenvironments, making CCR8 a relevant target for cancer immunology research and therapeutic intervention studies[1][3]. Experimental evidence further indicates that CCR8 signaling interacts with innate immune pathways, including Toll-like receptor 4 signaling, supporting a broader role in inflammatory regulation beyond chemokine-directed cell migration[4]. Compared with related chemokine receptors such as CCR4, which recognizes multiple ligands including CCL17 and CCL22, CCR8 displays a more restricted ligand profile centered on CCL1-mediated signaling, supporting its utility as a comparatively selective immunological target[1][5]. For experimental applications, both antagonistic antibodies and synthetic CCR8 agonists or antagonists have been developed to investigate receptor activation mechanisms, ligand bias, and immune-cell functions in cancer and inflammatory disease models[1][5].

製品番号 製品名 製品効果 純度
  • HY-119217
    AZ084 Antagonist 99.70%
    AZ084 is a potent, selective, allosteric and oral active CCR8 allosteric antagonist, with a Ki of 0.9 nM. Has potential to treat asthma. AZ084 restrains the formation of the immunologically tolerant pre-metastatic niche (PMN) and tumor cells metastasis in lung by downregulating Treg differentiation. AZ084 can be used in studies of asthma and cancer.
  • HY-122219
    R243 Antagonist 98.09%
    R243 is a potent and selective CCR8 antagonist. R243 inhibits CCL1/CCR8 interaction and inhibits CCR8 signaling and chemotaxis. R243 has antinociceptive and anti-inflammatory effects.
  • HY-124416
    ML604086 Inhibitor 99.78%
    ML604086 is a selective CCR8 inhibitor, inhibiting CCL1 binding to CCR8 on circulating T-cells. ML604086 inhibits CCL1 mediated chemotaxis and increases in intracellular Ca2+ concentrations.
  • HY-P990914
    Denikitug 99.00%
    Denikitug (GS-1811; JTX-1811) is a humanized monoclonal antibody against CCR8 receptor with a KD of 16.8 pM. Denikitug specifically binds to human CCR8, inhibits CCL1-induced downstream CCR8 signaling. Denikitug selectively depletes cells expressing CCR8 via antibody-dependent cellular cytotoxicity (ADCC). Denikitug promotes anti-tumor immunity and can be used for the research of cancer and immunology.
  • HY-121885
    LMD-009 Agonist 99.35%
    LMD-009 is a selective CCR8 nonpeptide agonist. LMD-009 mediates chemotaxis, inositol phosphate accumulation, and calcium release in high potencies with EC50s from 11 to 87 nM.
  • HY-P991481A
    S-531011 (FUT8-KO) Inhibitor
    S-531011 (FUT8-KO) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. S-531011 (FUT8-KO) can be used for the research of cancer immunity.
  • HY-P991135A
    Enzelkitug (FUT8-KO) Inhibitor
    Enzelkitug (RO-7502175; RG-6411) (FUT8-KO) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. Enzelkitug (FUT8-KO) can be used for the research of various solid tumors and hematological malignancies.
  • HY-P991942A
    Lanerkitug (FUT8-KO) Inhibitor
    Lanerkitug (FUT8-KO) (BAY3375968 (FUT8-KO)) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Lanerkitug (HY-P991942) selectively depletes human CCR8+Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Lanerkitug can be used in the research of solid tumors.
  • HY-101038A
    ZK756326 dihydrochloride Agonist 99.87%
    ZK756326 dihydrochloride is a nonpeptide chemokine receptor agonist for the CC chemokine receptor CCR8.
  • HY-144197
    CCR8 antagonist 1 Antagonist 99.50%
    CCR8 antagonist 1 (Compound 15) is a potente human CCR8 antagonist with a Ki of 1.6 nM. CCR8 antagonist 1 has high safety and metabolic stability. CCR8 antagonist 1 can be used to study diseases such as asthma and multiple sclerosis.
  • HY-P991061
    Tagmokitug Inhibitor 99.9%
    Tagmokitug (CHS-114; SRF-114) is a fully human IgG1 antibody targeting CCR8. Tagmokitug selectively binds to human CCR8 (Kd = 502 pM) and mediates the death of CCR8-expressing cells via antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. Tagmokitug selectively eliminates intratumoral regulatory T cells, induces tumor growth inhibition, remodels the tumor immune microenvironment, and promotes the differentiation of cytotoxic CD8+ T cell subsets. Tagmokitug can be used for the research of solid tumors.
  • HY-P991481
    S-531011 Inhibitor 98.38%
    S-531011 is a high-affinity, selective, and reversible CCR8 ligand with antibody-dependent cellular cytotoxicity (ADCC) against CCR8-expressing cells. S-531011 induces the death of tumor-infiltrating CCR8+ regulatory T cells while preserving regulatory T cells in peripheral blood, thereby reinvigorating anti-tumor immunity. The combination of S-531011 with anti-PD-1 antibody effectively inhibits tumor growth, and S-531011 can be used for research on advanced solid tumors and various cancers including non-small cell lung cancer, ovarian cancer, colon cancer, breast cancer, and pancreatic ductal adenocarcinoma.
  • HY-P991942
    Lanerkitug Inhibitor
    Lanerkitug (BAY3375968) is a fully human monoclonal IgG1 anti-human CCR8 antibody. Lanerkitug selectively depletes human CCR8+ Tregs via antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Lanerkitug can be used in the research of solid tumors.
  • HY-176800
    LMD-902 Agonist
    LMD-902, a LMD-009 (HY-121885) analog, is a CCR8 agonist with an EC50 of 15  nM. LMD-902 has a superior binging capacity depending on key residues such as PheVI:16. LMD-902 can be used for inflammation diseases like bronchial asthma and central nervous system diseases like multiple sclerosis research.
  • HY-153669
    SB-649701 Antagonist
    SB-649701 is a potent human CCR8 antagonist, with a pIC50 of 7.7. AZ084 can be used for the research of asthma.
  • HY-P992334
    CM369 Inhibitor
    CM369 is a humanized monoclonal antibody against CCR8 that possesses potential immunomodulatory and anti-tumor activities. CM369 can be used in cancer research.
  • HY-P991135
    Enzelkitug Inhibitor
    Enzelkitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the human C-C motif chemokine receptor 8 (CCR8). Enzelkitug is promising for research of various solid tumors and hematological malignancies.
  • HY-P991944A
    ZL-1218 (FUT8-KO) Inhibitor
    ZL-1218 (FUT8-KO) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. ZL-1218 (FUT8-KO) can be used for the research of solid tumour.
  • HY-176799
    LMD-584 Agonist
    LMD-584 is an agonist of CCR8. LMD-584 is also an analog of LMD-009 (HY-121885).
  • HY-P992365
    HFB101110 Inhibitor
    HFB101110 is a human-derived inhibitor and Treg depleter that specifically targets CCR8. It does not bind to the homologous CCR4 receptor and is mainly used in research on solid tumors, renal cell carcinoma and colorectal cancer. HFB101110 blocks hCCL1 binding by interacting with the N-terminal extracellular domain of hCCR8, thereby inhibiting hCCL1-induced calcium influx, chemotaxis and downstream signaling pathways. Meanwhile, HFB101110 can mediate ADCC effects to specifically deplete CCR8-positive cells, including intratumoral Tregs. HFB101110 exhibits favorable anti-tumor activity and pharmacokinetic properties.
製品番号 製品名 / Synonyms Species Source